DNDi and our partners are supporting global elimination efforts by accelerating access to affordable treatments. Following development of ravidasvir, the first all-oral treatment for hepatitis C developed through South-South collaboration, we are now working with national governments, civil society organizations, and other partners to help enable access to affordable direct-acting antiviral treatments and foster the political will needed for wide-scale roll-out of test-and-treat strategies. 

Our progress in 2025 includes:

Registration & access

Ravidasvir + sofosbuvir: The results of the EASE study testing shorter regimens (8 to 12 weeks) of ravidasvir and sofosbuvir, showing non-inferiority of the shorter regimen in patients living with HCV without cirrhosis and reducing the cost of treatment by 40%, were presented at the 2025 European Association for the Study of the Liver (EASL) Congress conference in May. The shorter 8-week regimen was approved by the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia, with safety evaluation to monitor any development of resistance to continue for 5 years.

In June, DNDi, the Government Pharmaceutical Organisation (GPO) of Thailand, and Pharco Pharmaceuticals signed an agreement to submit the dossier for registration of ravidasvir in Thailand, where HCV remains a significant public health concern. The dossier was submitted to regulatory authorities in Thailand in July.

In September, DNDi and Imperial College London presented a poster modelling HCV treatment resistance at 8th Conference on Liver Disease in Africa (COLDA) 2025.

In December, the preliminary results of the Dreamlopments-led C-FREE-SEA study to evaluate the use of ravidasvir in marginalized populations were accepted for presentation at the World Hepatitis Summit, to be held in Thailand in April 2026.

Photo credit: Abang Amirrul Hadi-DNDi